David re-joined SV as a Venture Partner in 2021 having previously been both a Venture Partner and Partner at SV.
Previously, David was CEO of Ophthotech (now Iveric Bio), a biotech focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs initially funded by SV. Under his leadership, Ophthotech entered into one of the largest ex-US partnering transactions ever in the biotechnology industry at that time with Novartis .
Prior to joining Opthotech, David led the development and successful commercialization of Macugen®, the first FDA-approved anti-VEGF pharmacological treatment for wet AMD, which Eyetech partnered with Pfizer whilst he was CEO of Eyetech. David co-founded the Company and SV was the first investor.
David has significant medical, drug development, and commercial experience in ophthalmology, and in his career has served on approximately 20 Boards of both public and private companies.
Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from the Johns Hopkins University School of Medicine. He completed his ophthalmology residency at the Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.